Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
L.D. Cripe; S. Hinton (Profiled Author: Larry D. Cripe)
Current treatment options in oncology. 2000;1(1):9-17.Abstract
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction. Thus, induction therapy for newly diagnosed patients with AML should consist of cytarabine (100 mg/m(2) as a continuous intravenous infusion over 24 hours for 7 days) and daunorubicin, idarubicin, or mitoxantrone. Meta-analysis demonstrates a modest benefit for idarubicin. Most patients who achieve a remission should receive further therapy with two to four cycles of high-dose cytarabine. Allogeneic stem cell transplant is reserved for patients with poor risk features. There is no role for autologous stem cell transplant in first remission outside a clinical trial. The majority of adults relapse. Salvage therapy usually consists of high-dose cytarabine. Allogeneic or autologous stem cell transplantation is preferred in second or subsequent remission. Uncommon diseases such as AML, for which the outcome remains poor, should be treated on clinical trials whenever possible.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Sherif S. Farag; Stephen L. George; Edward J. Lee; Maria Baer; Richard K. Dodge; Brian Becknell; Todd Fehniger; Lewis R. Silverman; Jeffrey Crawford; Clara D. Bloomfield; et al.
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420Clinical Cancer Research. 2002;8(9):2812-2819.
Robert J. Soiffer; Diane Fairclough; Michael Robertson; Edwin Alyea; Kenneth Anderson; Arnold Freedman; Lini Bartlett-Pandite; David Fisher; Robert L. Schlossman; Richard Stone; et al.Blood. 1997;89(8):3039-3047.
Larry D. Cripe; Kevin Rader; Martin S. Tallman; Michael S. Gordon; Elisabeth Paietta; John Bennett; Donna Neuberg; Mark R. Litzow; Timothy E. O'Brien; et al.
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Leukemia Research. 2006;30(7):823-827.
Appears in this Document